Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 10 Carcinoma, Non-Small-Cell Lung 5 Breast Neoplasms 4 Uterine Cervical Neoplasms 3 Uterine Cervical Dysplasia 3 Glioma 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Brain Neoplasms 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Thyroid Neoplasms 2 Rectal Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Oropharyngeal Neoplasms 2 Neoplasms 2 Mouth Neoplasms 2 Melanoma 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Ependymoma 2 Uveal Melanoma 1 Uterine Neoplasms 1 Uterine Diseases 1 Uterine Cervical Diseases 1 Urogenital Neoplasms 1 Urogenital Diseases 1 Ureteral Neoplasms 1 Thyroid Nodule 1

Interventions

Specimen Handling 8 pembrolizumab 7 enfortumab vedotin 7 Magnetic Resonance Spectroscopy 6 avelumab 4 Nivolumab 4 Gemcitabine 3 cabozantinib 2 Ipilimumab 2 Immunoglobulin G 2 Disulfides 2 Cisplatin 2 Carboplatin 2 CTLA-4 Antigen 2 Biopsy 2 vinflunine 1 tremelimumab 1 tocilizumab 1 tamibarotene 1 relatlimab 1 eribulin 1 erdafitinib 1 durvalumab 1 copanlisib 1 atezolizumab 1 Watchful Waiting 1 Standard of Care 1 Propranolol 1 Practice Guidelines as Topic 1 Plasmapheresis 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ureteral Neoplasms × Watchful Waiting × 1 year × Clear all

NCT03244384 2026-05-29

AMBASSADOR

National Cancer Institute (NCI)

Phase 3 Active not recruiting

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡